Vle Therapeutics
Vle Therapeutics, headquartered in Ireland, is a pioneering company in the biotechnology sector, specialising in innovative therapeutic solutions. Founded in 2018, Vle Therapeutics has quickly established itself as a leader in the development of cutting-edge treatments for various diseases, focusing on areas such as oncology and autoimmune disorders. The company’s core offerings include advanced drug delivery systems and proprietary compounds that enhance therapeutic efficacy while minimising side effects. Vle Therapeutics is recognised for its commitment to research and development, achieving significant milestones in clinical trials that underscore its market position. With a strong operational presence across Europe and North America, Vle Therapeutics continues to drive advancements in the biopharmaceutical industry, making a meaningful impact on patient care.
DitchCarbon Score
How does Vle Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vle Therapeutics's score of 6 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Vle Therapeutics's reported carbon emissions
Vle Therapeutics, headquartered in Ireland, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by 2030, using 2022 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its Scope 1 and 2 commitments, Vle Therapeutics is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These initiatives reflect the company's dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. As a small to medium enterprise, Vle Therapeutics is actively contributing to the global effort to combat climate change through these strategic commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vle Therapeutics is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
